Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: A revised statement from a Canadian National Expert Group

Current Oncology

Volumn 17, Issue 3, 2010, Pages 49-64

  Kocha, W ^a   Maroun, J ^b   Kennecke, H ^c   Law, C ^d   Metrakos, P ^e   Ouellet, J F ^f   Reid, R ^g   Rowsell, C ^d   Shah, A ^c   Singh, S ^h   van Uum, S ⁱ   Wong, R ^j  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁱ ST JOSEPH S HEALTH CENTRE   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

Carcinoid heart disease; Carcinoid syndrome; Carcinoid tumour; Clinical management; Diagnosis; Guidelines; Neuroendocrine tumours; Surgery

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; CAPECITABINE; CHROMOGRANIN A; CISPLATIN; COLESTYRAMINE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; KI 67 ANTIGEN; LUTETIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE LU 177; MAMMALIAN TARGET OF RAPAMYCIN; NERVE CELL ADHESION MOLECULE; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PEGINTERFERON ALPHA; PENTETREOTIDE IN 111; PLACEBO; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SYNAPTOPHYSIN; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; AUTOIMMUNE DISEASE; BONE METASTASIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOID SYNDROME; CLINICAL TRIAL; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE TITRATION; ECHOGRAPHY; ENDOSCOPIC BIOPSY; FATIGUE; FLATULENCE; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; LIVER METASTASIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; MENTAL DISEASE; NAUSEA; NEEDLE BIOPSY; NEUROENDOCRINE TUMOR; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PANCREAS TUMOR; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOFREQUENCY ABLATION; SCINTIGRAPHY; STEATORRHEA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77953116589     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i3.484     Document Type: Article

References (94)

1. Rindi G, Klöppel G, Alhman H, et al.; all other Frascati Con-sensus Conference participants; and the European Neuroendo-crine Tumour Society (enets). TNM staging of foregut (neuro) endocrine tumours: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
2. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadel-phia, PA: Lippincott Williams and Wilkins; 2001: 1813-33.
3. Modlin IM, Lye KDA, Kidd M. A 5-decade analysis of 13,715 carcinoid tumours. Cancer 2003;97:934-59.
4. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointes-tinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 2006;13:67-76.
5. Öberg K, Astrup L, Eriksson B, et al. On behalf of the Nor-dic NE Tumour Group. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part i-general overview. Acta Oncol 2004;43:617-25.
6. Öberg K, Astrup L, Eriksson B, et al. on behalf of the Nor-dic NE Tumour Group. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part ii-specific ne tumour types. Acta Oncol 2004;43:626-36.
7. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (enets). Neuroendocrinology 2004;80:394-424.
8. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumours. V.1.2010. Jenkintown, PA: nccn; 2010. [Available online at: www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf; cited April 15, 2010]
9. Ramage JK, Davies AH, Ardill J, et al. On behalf of the UK-NETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (includ-ing carcinoid) tumours. Gut 2005;54(suppl 4):iv1-16.
10. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
11. Ontario Cancer Registry (ocr). Cancer Incidence, Mortality, Survival, and Prevalence in Ontario [ocr and seer*Stat cd-rom]. Toronto, ON: ocr; 2004.
12. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neu-roendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
13. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumour or larger problem? Am J Gastroenterol 2004;99:23-32.
14. Maggard M, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumours. Ann Surg 2004;240:117-22.
15. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumours. Cancer 1997;79:813-29.
16. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epide-miology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 2000;83:952-5.
17. Williams ED, Sandler M. The classification of carcinoid tu-mours. Lancet 1963;1:238-9.
18. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Digestion 1994;55(suppl 3):11-23.
19. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the who classifica-tion. Ann N Y Acad Sci 2004;1014:13-27.
20. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
21. College of American Pathologists (cap). Home CAP Reference Resources and Publications Cancer Cancer Protocols and Checklists [Web resource]. Northfield, IL: cap; 2010. Available at: http//www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cntvwrPtltactionactionForm.contentReference=committees%2Fcancer%2Fcancer_protocols%2Fprotocols_index.html&_state=maximized&_pageLabel=cntvwrcited April 15, 2010
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2009.
23. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal in-cluding a grading system. Virchows Arch 2007;451:757-62.
24. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic Consen-sus Process to the development of a minimum pathology data set. Am J Surg Pathol 2010;34:300-13.
25. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
26. Öberg K. Diagnosis and treatment of carcinoid tumours. Expert Rev Anticancer Ther 2003;3:863-77.
27. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumours. Endocr Relat Cancer 2007;14:221-32.
28. Elie N, Plancoulaine B, Signolle JP, Herlin P. A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A 2003;56:37-45.
29. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neu-ron specific enolase, carcinoembryonic antigen, and hydroxy-indole acetic acid evaluation in patients with neuroendocrine tumours. Cancer 1999;86:858-65.
30. van der Horst-Schrivers AN, Wymenga AN, Links TP, Wil-lemse PH, Kema IP, de Vries EG. Complications of midgut carcinoid tumours and carcinoid syndrome. Neuroendocrinol-ogy 2004;80(suppl 1):28-32.
31. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcin-oid tumours and carcinoid syndromes. Ann Clin Biochem 2003;40(pt 6):612-27.
32. de Herder WW. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract Res Clin Gastroenterol 2005;19:705-15.
33. Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003;348:1005-15.
34. Plöckinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendo-crinology 2004;80(suppl 1):35-8.
35. Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumours. Am J Med 1986;81:41-8.
36. Rorstad O. Prognostic indicators for carcinoid neuroen-docrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60.
37. Agranovich AL, Anderson GH, Manji M, Acker BD, Macdon-ald WC, Threlfall WJ. Carcinoid tumour of the gastrointestinal tract: prognostic factors and disease outcome. J Surg Oncol 1991;47:45-52.
38. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
39. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
40. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnor-malities. Circulation 1988;77:264-9.
41. Denney WD, Kemp WE Jr, Anthony LB, Oates JA, Byrd BF 3rd. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998;32:1017-22.
42. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocar-diography. Circulation 1995;92:790-5.
43. Eriksson B, Öberg K, Stridsberg M. Tumour markers in neu-roendocrine tumours. Digestion 2000;62(suppl 1):33-8.
44. Öberg K, Janson ET, Eriksson B. Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S1602.
45. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clini-cal review. Oncologist 2005;10:123-31.
46. Joy T, Walsh G, Tokmakejian S, Van Uum SH. Increase of uri-nary 5-hydroxyindoleacetic acid excretion but not serum chro-mogranin A following over-the-counter 5-hydroxytryptophan intake. Can J Gastroenterol 2008;22:49-53.
47. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol 2004;60:644-52.
48. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendo-crine tumours of the gastroenteropancreatic system. Ann Oncol 2004;15:966-73.
49. Jensen TB, Hilsted L, Rehfeld JF. Library of sequence-specific radioimmunoassays for human chromogranin A. Clin Chem 1999;45:549-660.
50. Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic ct versus mr imaging in tumor detection. Radiology 2000;216:163-71.
51. Vick C, Zech CJ, Höpfner S, Waggershauser T, Reiser M.Imaging of neuroendocrine tumours of the pancreas [German]. Radiologe 2003;43:293-300.
52. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80(suppl 1):51-6.
53. Frilling A, Malago M, Martin H, Broelsch CE. Use of soma-tostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumours. Surgery 1998;124:1000-4.
54. Kisker O, Bartsch D, Weinel RJ, et al. The value of somatosta-tin-receptor scintigraphy in newly diagnosed endocrine gastro-enteropancreatic tumors. J Am Coll Surg 1997;184:487-92.
55. Kwekkeboom DJ, Krenning EP. Somatostatin receptor scin-tigraphy in patients with carcinoid tumours. World J Surg 1996;20:157-61.
56. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imag-ing and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15-27.
57. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumours. Endocr Rev 2004;25:458-511.
58. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001;28:478-82.
59. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of soma-tostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
60. Öberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19:265-76.
61. Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumours. Yale J Biol Med 1997;70:509-22.
62. Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-dopa pet: a prospective diagnostic accuracy study. Lancet Oncol 2006;7:728-34.
63. Schnirer II, Yao JC, Ajani JA. Carcinoid-a comprehensive review. Acta Oncol 2003;42:672-92.
64. Woodside KJ, Townsend CM Jr, Mark Evers B. Current man-agement of gastrointestinal carcinoid tumours. J Gastrointest Surg 2004;8:742-56.
65. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumours. Cancer 1997;79:830-4.
66. Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998;18:605-19.
67. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associ-ated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003;133:375-82.
68. Coppa J, Pulvirenti A, Schiavo M, et al. Resection versus trans-plantation for liver metastases from neuroendocrine tumors. Transplant Proc 2001;33:1537-9.
69. Que FG, Sarmiento JM, Nagorney DM, et al. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumours. Cancer Control 2002;9:67-79.
70. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 2007;11:264-71.
71. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioemboliza-tion for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-9.
72. Arnold R, Müller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group [abstract 121]. Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2009;: Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=63&abstract ID=10363;cited March 23, 2010
73. Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeu-tic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47.
74. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation 2007;116:2860-5.
75. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. Carcinoid heart disease. Int J Cardiol 2008;129:318-24.
76. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-con-trolled, double-blind, prospective, randomized study on the ef-fect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid Study Group. J Clin Oncol 2009;27:4656-63.
77. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:617-36.
78. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG on behalf of the Eastern Cooperative Oncology Group. Phase ii/iii study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904.
79. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumours. J Gastrointest Surg 2004;8:208-12.
80. Fine RL, Fogelman DR, Schreibman DM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine [abstract 4216]. Proc Am Soc Clin Oncol 2005;23:. [Available online at: meeting.ascopubs.org/cgi/content/abstract/23/16_ suppl/4216; cited March 30, 2010]
81. Isacoff WH, Moss RA, Pecora AL, Fine RL. Temozolomide/ capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review [abstract 14023]. Proc Am Soc Clin Oncol 2006;24(suppl):. [Available online at: meeting. ascopubs.org/cgi/content/abstract/24/18_suppl/14023; cited March 30, 2010]
82. Kulke MH, Stuart K, Enzinger PC, et al. Phase ii study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6.
83. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-dota 0,Tyr3] Octreotate: Toxicity, Efficacy, and Survival. J Clin Oncol 2008;26:2124-30.
84. Quaedvlieg PF, Lamers CB, Taal BG. Carcinoid heart disease: an update. Scand J Gastroenterol Suppl 2002;(236):66-71.
85. Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006;111:674-706.
86. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytrypt-amine receptor subtype messenger rna in interstitial cells from human heart valves. J Heart Valve Dis 2000;9:256-60.
87. Rajamannan NM, Caplice N, Anthikad F, et al. Cell prolif-eration in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-31.
88. Xu J, Jian B, Chu R, et al. Serotonin mechanisms in heart valve disease ii: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002;161:2209-18.
89. Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-22.
90. Hauso Ø, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, Waldum HL. Long-term serotonin effects in the rat are pre-vented by terguride. Regul Pept 2007;143:39-46.
91. Musunuru S, Carpenter JE, Sippel RS, Kunnimalaiyaan M, Chen H. A mouse model of carcinoid syndrome and heart disease. J Surg Res 2005;126:102-5.
92. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac val-vulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-41.
93. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovas-cular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006;22:23-45.
94. Wilhelmi M, Fritz MK, Fischer S, Haverich A, Harringer W. Triple valve replacement in a patient with severe carcinoid heart disease. Cardiovasc Surg 2002;10:287-90.